Bayer tweaks anti-counterfeiting tactics

A Bayer team from various corporate disciplines assigns anti-counterfeiting features to products based on evaluated risk level. Risk criteria include patient health ramifications, product properties, supply chain considerations and economic drivers, all considered in light of a potential counterfeiting scenario. 

The team then selects security features to incorporate with layout, design and packaging, an anonymous spokesperson tells Securing Pharma. The packaging for one critical medicine has seven security features that nearly assure complete protection against counterfeiting, according to the spokesperson. Most of these features can be seen with the naked eye, according to Bayer, although some require ultraviolet light and decoder templates.

But the effort doesn't stop there. Tie-ins with serialization and traceability efforts come next, followed by use of analytics for physical, chemical and packaging material.

- see the story

Suggested Articles

The FDA asked five drugmakers to pull their version of extended-release metformin off U.S. shelves after finding carcinogen contamination.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.

GSK has formed several collaborations across the globe that will use its AS03 adjuvant to develop vaccines against the novel coronavirus.